Concepedia

N. Shand

NS

20

Publications

2.1K

Citations

16

H-Index

1991

Active since

Affiliations

Novartis (Switzerland)(Current)

Lincoln University

Royal Marsden Hospital

Sarah Cannon

Dana-Farber Cancer Institute

N. Shand is an author at Novartis (Switzerland) specializing in medicine, radiation oncology, and cancer therapeutics.

Top concepts

Publications per year

1991–2009

20

Publications

20

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo et al. · Journal of Clinical Oncology · 2008 · 528 citations

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O’Donnell, Sandrine Faivre, Howard A. Burris et al. · Journal of Clinical Oncology · 2008 · 476 citations

A Phase 1-2 Clinical Trial of Gene Therapy for Recurrent Glioblastoma Multiforme by Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene Followed by Ganciclovir

N. Shand, Friedrich Weber, Luigi Mariani et al. · Human Gene Therapy · 1999 · 253 citations

, , +19

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

Chiaki Tanaka, Terence O’Reilly, John M. Kovarik et al. · Journal of Clinical Oncology · 2008 · 209 citations

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

M. Campone, Vincent Lévy, Emmanuelle Bourbouloux et al. · British Journal of Cancer · 2009 · 97 citations · Full text

Rows per page

1–5 of 20